HPLC-UV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Ubiquitin molecules are cleaved off the protein immediately prior to destruction and are recycled for further use. Although the majority of protein substrates are ubiquitylated, there are examples of non-ubiquitylated proteins targeted to the proteasome. The polyubiquitin chains are recognised by a subunit of the proteasome: S5a/Rpn10. This is achieved by a ubiquitin-interacting motif (UIM) found in a hydrophobic patch in the C-terminal region of the S5a/Rpn10 unit. Lysine 63-linked chains are not associated with proteasomal degradation of the substrate protein. Instead, they allow the coordination of other processes such as endocytic trafficking, inflammation, translation, and DNA repair. In cells, lysine 63-linked chains are bound by the ESCRT-0 complex, which prevents their binding to the proteasome. This complex contains two proteins, Hrs and STAM1, that contain a UIM, which allows it to bind to lysine 63-linked chains. Methionine 1-linked (or linear) polyubiquitin chains are another type of non-degradative ubiquitin chains. In this case, ubiquitin is linked in a head-to-tail manner, meaning that the C-terminus of the last ubiquitin molecule binds directly to the N-terminus of the next one. Although initially believed to target proteins for proteasomal degradation, linear ubiquitin later proved to be indispensable for NF-kB signaling. Currently, there is only one known E3 ubiquitin ligase generating M1-linked polyubiquitin chains - linear ubiquitin chain assembly complex (LUBAC).
=== Worldwide === In 1839, the world's oldest international human rights organization, Anti-Slavery International, was formed in Britain by Joseph Sturge, which campaigned to outlaw slavery in other countries. There were celebrations in 2007 to commemorate the 200th anniversary of the abolition of the slave trade in the United Kingdom through the work of the British Anti-Slavery Society. In the 1860s, David Livingstone's reports of atrocities within the Arab slave trade in Africa stirred up the interest of the British public, reviving the flagging abolitionist movement. The Royal Navy throughout the 1870s attempted to suppress "this abominable Eastern trade", at Zanzibar in particular. In 1905, the French abolished indigenous slavery in most of French West Africa. On December 10, 1948, the United Nations General Assembly adopted the Universal Declaration of Human Rights, which declared freedom from slavery is an internationally recognized human right. Article 4 of the Universal Declaration of Human Rights states:
=== Osteoconduction === Osteoconduction is termed as "the property of a material to support tissue ingrowth, osteoprogenitor cell growth, and development for bone formation to occur". In the context of bone grafting it occurs when the bone graft material serves as a scaffold for new bone growth that is perpetuated by the native bone. Osteoblasts from the margin of the defect that is being grafted utilize the bone graft material as a framework upon which to spread and generate new bone. Osteoblasts do not originate from the donor tissue, but through the internal ingrowing of the host's cells. The proper bonding of bioactive chemicals (Beta-Tricalcium Phosphate) in implants used in bone grafting surgery allow the promotion of osteoconductivity in the area of a defect. In the very least, a bone graft material should be osteoconductive by being made up of these bioactive chemicals.
== Life and career == Li was born in Guangzhou and educated at the Nanjing University. In 1935, he immigrated to the US, where he took up postgraduate studies at the University of California, Berkeley, and later joined the staff. He became professor in 1950. He served as Director of the Hormone Research Laboratory at Berkeley from 1950 to 1967 and at UCSF from 1967 until his retirement in 1983. In 1955, he was elected as Academician of Academia Sinica, Republic of China. Li dedicated his entire academic career studying the pituitary-gland hormones. In collaboration with various co-workers, he isolated several protein hormones, including adrenocorticotropic hormone (ACTH), which stimulates the adrenal cortex to increase its secretion of corticoids. In 1956, Li and his group showed that ACTH consists of 39 amino acids arranged in a specific order, and that the whole chain of the natural hormone is not necessary for its action. He isolated another pituitary hormone called melanocyte-stimulating hormone (MSH) and found that not only does this hormone produce some effects similar to those produced by ACTH, but also that part of the amino acid chain of MSH is the same as that of ACTH.
Serine–tRNA ligase, cytoplasmic, also called seryl-tRNA synthetase 1 is an enzyme that in humans is encoded by the gene SARS1 (previously SARS). SARS belongs to the class II amino-acyl tRNA family and is found in all humans, and functions as a serine–tRNA ligase which is involved in protein translation and is related to several bacterial and yeast counterparts.
Sources: en.wikipedia.org
Machine vision systems often require bright and homogeneous illumination, so features of interest are easier to process. LEDs are often used. Barcode scanners are the most common example of machine vision applications, and many of those scanners use red LEDs instead of lasers. Optical computer mice use LEDs as a light source for the miniature camera within the mouse. LEDs are useful for machine vision because they provide a compact, reliable source of light. LED lamps can be turned on and off to suit the needs of the vision system, and the shape of the beam produced can be tailored to match the system's requirements.
The GTP-binding domain is conserved in both EF-1alpha/EF-Tu and also in EF-2/EF-G and thus seems typical for GTP-dependent proteins which bind non-initiator tRNAs to the ribosome. The GTP-binding translation factor family also includes the eukaryotic peptide chain release factor GTP-binding subunits and prokaryotic peptide chain release factor 3 (RF-3); the prokaryotic GTP-binding protein lepA and its homologue in yeast (GUF1) and Caenorhabditis elegans (ZK1236.1); yeast HBS1; rat Eef1a1 (formerly "statin S1"); and the prokaryotic selenocysteine-specific elongation factor selB.
Some experts have argued that it is too early to regulate AI, expressing concerns that regulations will hamper innovation and it would be foolish to "rush to regulate in ignorance". Others, such as business magnate Elon Musk, call for pre-emptive action to mitigate catastrophic risks. In September 2026, Musk proposed that leading AI companies allow competitors to test their models before public release, arguing the independent testing by rival companies could identify safety concerns that might be missed through internal evaluations. Outside of formal legislation, government agencies have put forward ethical and safety recommendations. In March 2021, the US National Security Commission on Artificial Intelligence reported that advances in AI may make it increasingly important to "assure that systems are aligned with goals and values, including safety, robustness and trustworthiness". Subsequently, the National Institute of Standards and Technology drafted a framework for managing AI Risk, which advises that when "catastrophic risks are present – development and deployment should cease in a safe manner until risks can be sufficiently managed". In September 2021, the People's Republic of China (PRC) published ethical guidelines for the use of AI in China, emphasizing that AI decisions should remain under human control and calling for accountability mechanisms.
Cefadroxil (formerly trademarked as Duricef) is a broad-spectrum antibiotic of the cephalosporin type, effective in Gram-positive and Gram-negative bacterial infections. It is a bactericidal antibiotic. It was patented in 1967 and approved for medical use in 1978.
==== Uruguay ==== Cider fizz or fizz is a cider variety made by mixing and fermenting various fruit juices other than apple with cider, as ananá fizz (pineapple juice), frutilla fizz (strawberry juice) or durazno fizz (peach juice).
Sources: en.wikipedia.org
== External links == Clinical trial number NCT04625270 for "A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation (RAMP 201)" at ClinicalTrials.gov
embassy vehicles and staff were no longer immune from penalties for traffic violations. American diplomats were asked to show work contracts for all domestic help (cooks, gardeners, drivers and security staff) employed within their households. Indian authorities also conducted an investigation into the American Embassy School. Nancy J. Powell, the U.S. ambassador to India, resigned following the incident, which was widely seen by India "as fallout from the imbroglio." Some commentators suggested that the incident and response could lead to wider damage in U.S.–India relations. Former Finance Minister Yashwant Sinha called for the arrest of same-sex companions of US diplomats, citing the Supreme Court of India's upholding of Section 377 of the Indian Penal Code whereby homosexuality is illegal in India. Former State Department legal advisor John Bellinger questioned whether the decision to arrest and detain Khobragade was "wise policy ... even if technically permissible" under the Vienna Convention on Consular Relations, while Robert D. Blackwill, the former U.S. ambassador to India from 2001 to 2003, said the incident was "stupid." Nevertheless, within a year of the incident, U.S.-India relations were warming again, as U.S. President Obama visited India in January 2015.
In November 2018, Cava Group bought Zoës Kitchen, a restaurant chain with more than 250 locations, in a deal worth $300 million, taking the company private and helping Cava expand further into the suburbs. As of August 2021, there were 133 Cava locations. All Cava restaurants are company-owned, and none are franchised. In 2020, Cava Group converted seven of its Zoës Kitchen locations to Cava-branded restaurants, with plans to convert 50 more in 2021. It has additional off-premises and digital kitchens dedicated to preparing food for online orders. As of May 2026, Cava operated 474 restaurant locations in the United States.
Furthermore, loss-of-function mutations in the PCSK9 gene result in lower levels of LDL and protection against cardiovascular disease. In addition to its lipoprotein synthetic and pro-atherosclerotic effects, PCSK9 is involved in glucose metabolism and obesity, regulation of re-absorption of sodium in the kidney which is relevant in hypertension. Furthermore, PCSK9 may be involved in bacterial or viral infections and sepsis. In the brain the role of PCSK9 is still controversial and may be either pro-apoptotic or protective in the development of the nervous system. PCSK9 levels have been detected in the cerebrospinal fluid at a 50–60 times lower level than in serum.
In 1887 Johannes Wislicenus published a study of stereoisomerism in unsaturated compounds. Groth made a systematic classification of minerals based on their chemical composition and crystal structure and published his results in his 5-volume Chemische Kristallographie in 1906–1919, which contained crystalline morphology and physical property data on nearly 10,000 substances. In 1913 Walter Wahl summarised the known connections between chemical composition and crystalline form as isomorphism (Mitscherlich), morphotropism (Groth), and enantiomorphism (Pasteur and van 't Hoff). In his preface to Andreas Fock's An introduction to chemical crystallography Pope summarised the state of chemical crystallography in 1895 as follows:
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.